Lonza
LONN
Performance
About Lonza
Lonza is a leading contract development and manufacturing organization focused on the healthcare industry. Founded in Switzerland in 1897, it operates globally with about 19,000 employees across five continents and offers integrated biologics, small molecule, specialized modalities, and regulatory services to help pharmaceutical and biotech customers bring therapies to market. The company positions itself as a pioneer in the CDMO space with capabilities spanning mammalian biologics, small molecules, cell and gene therapy, and related manufacturing and development services. Lonza serves customers worldwide, delivering life-enhancing and life-saving treatments across diverse therapeutic areas.
Recent News
Addressing Manufacturing and Access Barriers in Advanced Therapeutics
Lonza Boosts Advanced Synthesis Capabilities for Bioconjugates
Apollo Closing in on €1.4bn Acquisition of Forvia Interior Systems Unit
Scalable Biologics Production Trends: Featuring Omar Wahab of Lonza — Breakthrough, Episode 250
Drug Digest: Examining the Architecture of Next-Gen Biotherapeutic Modalities
The Innovators Working to Make in Vivo Cell Therapy a Reality
Sidewinder Targets Solid Tumors with Bispecific ADCs on Novartis-Backed Funding
Dietary Fructo-Oligosaccharides Dose-Dependently Modulate the Microbiome and Suppress Type 2 Lung Inflammation in a Murine Model of House Dust Mite-Induced Allergic Asthma
PolyPeptide Shortlists EQT and IDG Capital as Bidding Process Advances